Actinium Pharmaceuticals vs Soligenix
ATNM and SNGX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ATNM and SNGX compare
Actinium Pharmaceuticals is the larger company, worth 6.2 times as much as Soligenix ($34.0M against $5.5M).
Actinium Pharmaceuticals scores higher on the StockData Score (10 against 6 for Soligenix), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ATNM | SNGX |
|---|---|---|
| Size and price | ||
| Market cap | $34.0M | $5.5M |
| Share price | $1.08 | $0.253 |
| Change, 1 year | −25.5% | −81.3% |
| Change, 5 years | −85.2% | −99.9% |
| Beta (5Y) | 1.17 | 0.67 |
| Employees | 25 | 14 |
| StockData Score | ||
| Total score | 10 (better) | 6 |
| Valuation score | 4 (better) | 1 |
| Growth score | 0 | 0 |
| Performance score | 1 (better) | 0 |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 3.0× | – |
| P/B | 1.1× | 0.8× (better) |
| EV/EBITDA | −0.3× | – |
| Fair value | $7.04 | – |
| Margin of safety | 84.7% | – |
| Profitability | ||
| Return on equity | 45.9% (better) | −242% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 4.08 (better) | 2.77 |
| Altman Z-score | −9.80 (better) | −35.19 |
| Piotroski F-score | 2 | 3 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 16.8% | 4.3% |
| Held by insiders | 5.9% | 0.69% |
| Short interest, % of float | 2.0% | 0.31% |
Go deeper
- ATNM stock overview
- ATNM income statement
- ATNM valuation and score
- SNGX stock overview
- SNGX income statement
- SNGX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.